Insider Selling: Pulse Biosciences (NASDAQ:PLSE) Insider Sells 4,600 Shares of Stock

Key Points

• Insider Kevin Patrick Danahy sold 4,600 shares of Pulse Biosciences at an average price of $18.53, reducing his ownership by 9.60% to a total of 43,298 shares.
• Pulse Biosciences' stock rose 2.2% to $19.87, with a market cap of $1.34 billion and a price-to-earnings ratio of -18.92.
• Two recent analyst reports rated Pulse Biosciences as an "outperform" with a price target of $22.00, while another issued a "sell" rating.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) insider Kevin Patrick Danahy sold 4,600 shares of the stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $18.53, for a total transaction of $85,238.00. Following the completion of the transaction, the insider directly owned 43,298 shares in the company, valued at approximately $802,311.94. This represents a 9.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kevin Patrick Danahy also recently made the following trade(s):

• On Thursday, September 18th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $18.49, for a total transaction of $369,800.00.
• On Friday, September 19th, Kevin Patrick Danahy sold 400 shares of Pulse Biosciences stock. The stock was sold at an average price of $18.48, for a total transaction of $7,392.00.

Pulse Biosciences Stock Up 2.2%

Shares of PLSE traded up $0.42 during mid-day trading on Tuesday, hitting $19.87. 148,951 shares of the company's stock were exchanged, compared to its average volume of 263,052. Pulse Biosciences, Inc has a 52 week low of $13.77 and a 52 week high of $25.00. The stock's 50-day simple moving average is $16.30 and its 200-day simple moving average is $16.27. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -18.92 and a beta of 1.79.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

Analyst Ratings Changes

PLSE has been the topic of a number of recent analyst reports. Oppenheimer initiated coverage on shares of Pulse Biosciences in a research note on Monday, July 7th. They issued an "outperform" rating and a $22.00 price objective on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Saturday, September 27th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $22.00.

Institutional Trading of Pulse Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC lifted its holdings in shares of Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock worth $44,000 after purchasing an additional 2,156 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock worth $26,000 after purchasing an additional 680 shares during the period. Brevan Howard Capital Management LP acquired a new position in shares of Pulse Biosciences during the second quarter worth $215,000. Bank of America Corp DE lifted its holdings in shares of Pulse Biosciences by 0.7% during the second quarter. Bank of America Corp DE now owns 783,536 shares of the company's stock worth $11,824,000 after purchasing an additional 5,775 shares during the period. Finally, Jane Street Group LLC lifted its holdings in shares of Pulse Biosciences by 20.6% during the second quarter. Jane Street Group LLC now owns 24,251 shares of the company's stock worth $366,000 after purchasing an additional 4,146 shares during the period. Institutional investors and hedge funds own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.